Olema Pharmaceuticals inc (OLMA)
10.67
+0.60
(+5.96%)
USD |
NASDAQ |
May 03, 16:00
10.66
-0.01
(-0.09%)
After-Hours: 20:00
Olema Pharmaceuticals Cash from Investing (TTM): -4.851M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -4.851M |
September 30, 2023 | 42.40M |
June 30, 2023 | 88.00M |
March 31, 2023 | 103.30M |
December 31, 2022 | 91.48M |
September 30, 2022 | 81.14M |
June 30, 2022 | 48.20M |
Date | Value |
---|---|
March 31, 2022 | 29.71M |
December 31, 2021 | -275.44M |
September 30, 2021 | -281.49M |
June 30, 2021 | -268.70M |
March 31, 2021 | -279.63M |
December 31, 2020 | -0.056M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-281.49M
Minimum
Sep 2021
103.30M
Maximum
Mar 2023
-48.15M
Average
29.71M
Median
Mar 2022
Cash from Investing (TTM) Benchmarks
Geron Corp | 32.62M |
Verastem Inc | -44.45M |
Fate Therapeutics Inc | 112.66M |
Karyopharm Therapeutics Inc | 7.94M |
Alpine Immune Sciences Inc | -55.56M |